Video Experimental Relacionado
Updated: Aug 9, 2026
08:24
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
Published on: May 25, 2020
Los estrógenos no anticonceptivos y el infarto de miocardio no fatal
JAMA
|April 3, 1978
Resumen
El uso de estrógenos aumenta significativamente el riesgo de infarto agudo de miocardio en mujeres mayores de 38 años que también fuman. Este hallazgo pone de relieve un riesgo sustancial para este grupo demográfico.
Área de la Ciencia:
- Cardiología Cardiología.
- Salud de la Mujer Salud de la Mujer.
- Farmacología Farmacología.
Sus antecedentes:
- El infarto agudo de miocardio (IAM) es poco común en mujeres jóvenes y sanas.
- Los factores que contribuyen a la IAM en este grupo demográfico no se comprenden completamente.
Objetivo del estudio:
- Investigar la asociación entre el uso de estrógenos no anticonceptivos y la IAM en mujeres premenopáusicas.
- Para identificar los factores de riesgo de IAM en mujeres menores de 46 años.
Principales métodos:
- Análisis retrospectivo de series de casos de 107 mujeres menores de 46 años hospitalizadas con IAM.
- Comparación del uso de estrógenos y los hábitos de fumar entre pacientes y controles.
Principales resultados:
- Se analizaron 17 mujeres (de 39 a 45 años) con IAM; 9 (53%) utilizaron estrógenos no anticonceptivos.
- Los usuarios de estrógenos tenían un riesgo relativo de 7.5 para IAM en comparación con los no usuarios.
- Todos menos uno de los 17 pacientes eran fumadores de cigarrillos.
Conclusiones:
- El uso no anticonceptivo de estrógenos se asocia con un aumento sustancial en el riesgo de IAM para las mujeres mayores de 38 años que fuman.
- El uso combinado de estrógenos y el tabaquismo representan un factor de riesgo significativo para la IAM en esta población.
- Se requiere más investigación para aclarar los mecanismos e informar las directrices clínicas.
Videos de Conceptos Relacionados
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...